- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07746375
Talking Circle for Native American Youth Living Well (AYoLi) (AYoLi)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78207
- American Indians In Texas at the Spanish Colonial Missions
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Participant criteria include Native American students in 5th or 6th grade (ages 10-12) and part of one of the Urban or Rural School After School Programs (5 Urban and 5 Rural).
Inclusion Criteria includes:
- Native American students enrolled in the 5th and 6th grades
- English-speaking
- Able to read and write English
- Willingness to provide Assent
- Not part of another Mental, Emotional or Behavioral Health Program
Exclusion Criteria includes
- Not Native American or in 5th or 6th grades,
- Non-English speakers,
- Unable to read and write English
- Unwillingness to provide Assent
- Part of another Mental, Emotional or Behavioral Health Program
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Talking Circle Intervention Group
The intervention group is receiving the talking circle intervention.
|
The intervention group is receiving a 10-week manual-based guide delivered in a talking circle format.
A talking circle is a sacred space for youth to share information with a group in a respectful way.
This instructional guide includes cultural materials as well as healthy ways to cope with and manage stress.
|
|
Other: Wait-List Control Group
Mental Health
|
The wait-list control group will receive general education materials on mental, emotional, and behavioral wellness as well as healthy ways to cope and manage stress.
The wait-list control group will receive the talking circle intervention at the completion of the 10 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Native Reliance Questionnaire
Time Frame: Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
Native Reliance Questionnaire is a cultural derived self-report instrument measuring self-reliance (or cultural identity), using a five-point Likert scale (1-5) varying from strongly disagree to strongly agree with a minimum score of 24 and a maximum score of 120.
A higher score indicates a better outcome or a strong connection to self-reliance cultural identity.
|
Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
|
Global Assessment of Individual Needs-Quick (GAIN-Q)- Sources of Stress Index
Time Frame: Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
The Global Assessment of Individual Needs-Quick (GAIN-Q) sources of stress scale is a self-report and brief assessment designed for use in diverse settings.
This assessment includes questions on general life problems such as sources of stress and health distress.
The sources of stress index, is a 13-item scale used to measure stress and includes a score of 0 to 13 with a minimum score of 0 and a maximum score of 13.
A higher score indicates higher sources or stress or a worse outcome.
|
Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
|
Generalized Anxiety Disorder-7 (GAD-7)
Time Frame: Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
The Generalized Anxiety Disorder-7 (GAD-7) is a brief self-report instrument used to evaluate anxiety using a 3-point Likert scale of 0 to 3. All 7 items are added together to create a total score. This scale has a score of 0 to 30, with 0 being the minimum score and 30 being the maximum score. Further evaluation is recommended when the score is 10 or greater. A higher score indicates a worse outcome and higher anxiety. disorder |
Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
|
Center for Epidemiologic Studies Depression Scale Revised-10 (CESD-R-10)
Time Frame: Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
The Center for Epidemiologic Studies Depression Scale-Revised-10 (CESD-R-10) is a 10-item self-reported instrument used to measure depression.
Items are summed to create a total score of 30.
The total score is calculated by finding the sum of 10 items.
The scale has a score of 0 to 30 with a minimum score of 0 and a maximum score of 30.
Any score equal to or above 10 is considered a worse outcome and defined as depressed.
|
Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global Youth Commercial Tobacco-Survey
Time Frame: Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
The Global Youth Commercial Tobacco Survey is a self-reported instrument measuring tobacco.
In this survey we are utilizing 13-items with a score of 0 to 13 with a minimum score of 0 and a maximum score of 13.
A higher score indicates a worse outcome and a higher use of commercial tobacco products.
|
Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
|
Suicidal Ideation Questionnaire-Junior-15
Time Frame: Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
Suicidal Ideation will be measured using the 15-item scale.
Each item is rated on a 7-point scale to indicate the frequency of having suicidal thoughts.
|
Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
|
Global Assessment of Needs Assessment-Q Substance Use Scale
Time Frame: Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
The Global Assessment of Needs Assessment-Q Substance Use scale is a sub-scale used to measure substance use.
For this study, we are utilizing 14 items with a score of 0 to 14, with a minimum score of 0 and a maximum score of 14.
A higher score indicates a worse outcome and higher substance use.
|
Baseline, 3-Month Post-Intervention and 6-Month-Post-Intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pediatric Symptom Checklist-17 (PSC-17) is a pre-screening tool
Time Frame: Baseline prior to start of the Intervention
|
The Pediatric Symptom Checklist is being used as a pre-screening tool.
The Pediatric Symptom Checklist-17 is not meant to be used as a diagnostic tool.
It includes a 17-item checklist.
Each of the 17 items is rated as "NEVER" (0), "SOMETIMES" (1), or "OFTEN" (2).
The total score is the sum of these ratings ranging from 0 to 34, with a minimum score of 0 and a maximum score of 34.
A higher score is a worse outcome and may indicate impairment in psycho-social functioning, which may include cognitive, emotional, and behavioral problems.
Higher scores suggest that individuals may be 'at risk' and require further assessment by a qualified health professional.
|
Baseline prior to start of the Intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jennifer N Baumgartner, PhD, National Center for Complementary and Integrative Health (NCCIH)
- Principal Investigator: John R Lowe, PhD, RN, University of Texas at Austin
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00004266-02
- UH3AT012547 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.